Gastrointestinal Adverse Events of Dipeptidyl Peptidase 4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-analysis

Clinical Therapeutics

Volumn 39, Issue 9, 2017, Pages 1780-1789.e33

  Wu, Shanshan ^a   Chai, Sanbao ^b   Yang, Jun ^c   Cai, Ting ^c   Xu, Yang ^c   Yang, Zhirong ^d   Zhang, Yuan ^e   Ji, Linong ^f   Sun, Feng ^c   Zhan, Siyan ^c  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY INTERNATIONAL HOSPITAL   (China)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e MCMASTER UNIVERSITY   (Canada)

^f PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

dipeptidyl peptidase 4 inhibitors; gastrointestinal adverse events; network meta analysis; type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALOGLIPTIN; ALPHA GLUCOSIDASE INHIBITOR; ANAGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GEMIGLIPTIN; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; KOMBIGLYZEXR; LINAGLIPTIN; LINAGLIPTIN PLUS METFORMIN; LIOVEL; LIRAGLUTIDE; METFORMIN; METFORMIN PLUS SITAGLIPTIN; METFORMIN PLUS VILDAGLIPTIN; PLACEBO; SAXAGLIPTIN; SIMVASTATIN PLUS SITAGLIPTIN; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; TENELIGLIPTIN; VILDAGLIPTIN;

ABDOMINAL BLEEDING; ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ABDOMINAL WALL HERNIA; ADVERSE EVENT; ANGIODYSPLASIA; ANUS FISTULA; ARTERY THROMBOSIS; ARTICLE; ASCITES; ATROPHIC GASTRITIS; CLINICAL EVALUATION; COCHRANE LIBRARY; COLITIS; COLON POLYP; CONGENITAL BLOOD VESSEL MALFORMATION; CONSTIPATION; CROHN DISEASE; DIABETIC STOMACH PARESIS; DIAPHRAGM HERNIA; DIARRHEA; DIGESTIVE SYSTEM INFLAMMATION; DIGESTIVE SYSTEM ULCER; DISEASE ASSOCIATION; DIVERTICULITIS; DIVERTICULOSIS; DRUG EFFECT; DRUG TOLERABILITY; DUODENAL ULCER BLEEDING; DUODENUM PERFORATION; DUODENUM ULCER; DYSKINESIA; DYSPEPSIA; DYSPHAGIA; EMBASE; ENTERITIS; EPIGASTRIC DISCOMFORT; EROSIVE GASTRITIS; ESOPHAGEAL FIBROSIS; ESOPHAGITIS; ESOPHAGITIS ULCERATIVE; ESOPHAGUS OBSTRUCTION; ESOPHAGUS SPASM; ESOPHAGUS STENOSIS; ESOPHAGUS VARICES; FEMORAL HERNIA; FIBROSIS; GASTRIC ULCER BLEEDING; GASTRITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ANGIODYSPLASIA; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL POLYPOSIS; GASTROINTESTINAL TELANGIECTASIA; GINGIVA BLEEDING; HEMATEMESIS; HEMORRHAGIC EROSIVE GASTRITIS; HEMORRHOID; HEMORRHOID HEMORRHAGE; HERNIA STRANGULATION; HIATUS HERNIA; HUMAN; ILEUS; INCIDENCE; INFLAMMATORY BOWEL DISEASE; INGUINAL HERNIA; INTESTINE DIVERTICULOSIS; INTESTINE ISCHEMIA; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; INTESTINE POLYP; IRRITABLE COLON; ISCHEMIC COLITIS; LARGE INTESTINE HEMORRHAGE; LARGE INTESTINE PERFORATION; MALLORY WEISS SYNDROME; MEDLINE; MEGACOLON; MESENTERIC ARTERY OCCLUSION; MESENTERIC ARTERY THROMBOSIS; MESENTERIC BLOOD VESSEL OCCLUSION; META ANALYSIS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OGILVIE SYNDROME; PANCREAS STONE; PANCREATITIS; PEPTIC ULCER; PERITONEUM ADHESION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM HEMORRHAGE; RECTUM POLYP; RECTUM PROLAPSE; RISK ASSESSMENT; RISK FACTOR; SMALL INTESTINE HEMORRHAGE; STOMACH ANTRUM VASCULAR ECTASIA; STOMACH EMPTYING; STOMACH HEMORRHAGE; STOMACH ULCER; SYSTEMATIC REVIEW; TELANGIECTASIA; TONGUE DISEASE; TREATMENT DURATION; ULCERATIVE COLITIS; UMBILICAL HERNIA; UPPER GASTROINTESTINAL BLEEDING; VOMITING; CHEMICALLY INDUCED; NETWORK META-ANALYSIS;

DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GASTROINTESTINAL DISEASES; HUMANS; NETWORK META-ANALYSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85027680161     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2017.07.036     Document Type: Article

References (40)

1. Shi, Z., Prevalence of diabetes among men and women in China. N Engl J Med, 362(25), 2010, 2425.
2. Dhillon, S., Sitagliptin: a review of its use in patients with type 2 diabetes mellitus. Drugs 70:4 (2010), 489–512.
3. Lajara, R., Use of the dipeptidyl peptidase-4 inhibitor linagliptin in combination therapy for type 2 diabetes. Expert Opin Pharmacother 13:18 (2012), 2663–2671.
4. McKeage, K., Linagliptin: an update of its use in patients with type 2 diabetes mellitus. Drugs 74:16 (2014), 1927–1946.
5. Keating, G.M., Vildagliptin: a review of its use in type 2 diabetes mellitus. Drugs 74:5 (2014), 587–610.
6. Jarvis, C.I., Cabrera, A., Charron, D., Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus. Ann Pharmacother 47:11 (2013), 1532–v1539.
7. Scott, L.J., Alogliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 70:15 (2010), 2051–2072.
8. Ali, S., Fonseca, V., Saxagliptin overview: special focus on safety and adverse effects. Expert Opin Drug Saf 12:1 (2013), 103–109.
9. Goda, M., Kadowaki, T., Teneligliptin for the treatment of type 2 diabetes. Drugs Today (Barc) 49:10 (2013), 615–629.
10. Esposito, K., Cozzolino, D., Bellastella, G., et al. Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Obes Metab 13:7 (2011), 594–603.
11. Van Valkenhoef, G., Lu, G., de Brock, B., et al. Automating network meta-analysis. Res Synth Methods 3:4 (2012), 285–299.
12. Higgins JPT. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. http://www.cochrane-handbook.org. accessed by December 20, 2016.
13. DerSimonian, R., Laird, N., Meta-analysis in clinical trials. Control Clin Trials 7:3 (1986), 177–188.
14. Higgins, J.P., Thompson, S.G., Quantifying heterogeneity in a meta-analysis. Stat Med 21:11 (2002), 1539–1558.
15. Scheen, A.J., DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. Diabetes Metab 38:2 (2012), 89–101.
16. Herman, G.A., Bergman, A., Stevens, C., et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 91:11 (2006), 4612–4619.
17. Chan, J.C., Scott, R., Ferreira, J.C., et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 10:7 (2008), 545–555.
18. He, Y., Serra, D., Wang, Y., et al. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin Pharmacokinet 46:7 (2007), 577–588.
19. Engel, S.S., Round, E., Golm, G.T., et al. Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies. Diabetes Ther 4:1 (2013), 119–145.
20. Cai, L., Cai, Y., Lu, Z.J., et al. The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. J Clin Pharm Ther 37:4 (2012), 386–398.
21. Berhan, A., Berhan, Y., Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized doubleblind controlled studies. BMC Endocr Disord, 13, 2013, 9.
22. Lehrke, M., Marx, N., Patel, S., et al. Safety and tolerability of linagliptin in patients with type 2 diabetes: a comprehensive pooled analysis of 22 placebo-controlled studies. Clin Ther 36:8 (2014), 1130–1146.
23. Scirica, B.M., Bhatt, D.L., Braunwald, E., et al., SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369:14 (2013), 1317–1326.
24. Wang, T., Gou, Z., Wang, F., et al. Comparison of GLP-1 Analogues versus sitagliptin in the management of type 2 diabetes: systematic review and meta-analysis of head-to-head studies. PLoS ONE, 9(8), 2014, e103798.
25. Stolar, M.W., Grimm, M., Chen, S., Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes. Diabetes Metab Syndr Obes 22:6 (2013), 435–444.
26. Monami, M., Iacomelli, I., Marchionni, N., Mannucci, E., Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 20:4 (2010), 224–235.
27. Karagiannis, T., Paschos, P., Paletas, K., et al. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta analysis. BMJ, 12(344), 2012, e1369.
28. Nathan, D.M., Buse, J.B., Davidson, M.B., et al. Zinman; AmericanDiabetes Association; European Association for Study of Diabetes, Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32:1 (2009), 193–203.
29. Garber, A., Henry, R., Ratner, R., et al., LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373:9662 (2009), 473–481.
30. Moretto, T.J., Milton, D.R., Ridge, T.D., et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 30:8 (2008), 1448–1460.
31. Russell-Jones, D., Cuddihy, R.M., Hanefeld, M., et al. DURATION-4 Study Group, Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naïve patients with type 2 diabetes (DURATION-4). Diabetes Care 35:2 (2012), 252–258.
32. Aronoff, S., Rosenblatt, S., Braithwaite, S., et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. Diabetes Care 23:11 (2000), 1605–1611.
33. Rosenstock, J., Dailey, G., Massi-Benedetti, M., et al. Reduced hypoglycemia risk with insulin glargine. Diabetes Care 28:4 (2005), 950–955.
34. Blonde, L., Merilainen, M., Karwe, V., Raskin, P., Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets—the TITRATE study. Diabetes Obes Metab 11:6 (2009), 623–631.
35. Rosenstock, J., Davies, M., Home, P.D., et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia, 51(3), 2008, 408v416.
36. Hollander, P., Cooper, J., Bregnhøj, J., Pedersen, C.B., A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther 30:11 (2008), 1976–1987.
37. Richard, K.R., Shelburne, J.S., Kirk, J.K., Tolerability of dipeptidyl peptidase-4 inhibitors: a review. Clin Ther 33:11 (2011), 1609–1629.
38. Iwamoto, Y., Kashiwagi, A., Yamada, N., et al. Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study. Diabetes Obes Metab 12:8 (2010), 700–708.
39. Iwamoto, Y., Tajima, N., Kadowski, T., et al. Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. Diabetes Obes Metab 12:7 (2010), 613–622.
40. Williams-Herman, D., Engel, S., Round, E., et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,426 patients with type 2 diabetes. BMC Endocr Disord, 10, 2010, 7.